|
Sign In to gain access to subscriptions and/or personal tools.
|
A one-year retrospective audit of the DIGAMI protocol
Harit N Buch
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire Trust, Stoke-on-Trent, ST4 6QG, UK, sharun{at}btinternet.com
David M Barton
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire Trust, Stoke-on-Trent, ST4 6QG, UK
George I Varughese
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire Trust, Stoke-on-Trent, ST4 6QG, UK
Ellen Hodgson
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire Trust, Stoke-on-Trent, ST4 6QG, UK
John HB Scarpello
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire Trust, Stoke-on-Trent, ST4 6QG, UK
Aim To assess the impact of post-MI diabetes-care upon changes in diabetes therapy and on cardiovascular risk factors.
Patients and methods Retrospective audit of case notes of patients with diabetes who were treated according to the DIGAMI protocol following an acute MI and who had completed at least one year of follow-up (n=86).
Results A majority of patients continued insulin therapy beyond the standard recommendation of three months (7%, 84%, 75% at 0, 3 and 12 months respectively) resulting in an increase in the number of patients attending hospital diabetes clinics (17%, 94% and 61%). A majority of patients belonged to DIGAMI low-risk group 1 (85%) which was the category of patients shown to have a significant survival benefit in the original DIGAMI cohort. At the end of one year an increased number of patients achieved targets for control of systolic BP (49, 59 and 77 at 0, 3 and 12 months), diastolic BP (44, 74 and 77%), TC (34, 73 and 80%) and HbA1C (24, 45 and 60%) (p<0.05 for all). Weight increased progressively (82 kg, 87 kg A and 88 kg, p<0.05). Percentage of smokers was reduced (31, 9 and 11, p<0.05).
Conclusion There was a significant rise in the number of patients receiving long-term insulin therapy, and attending secondary care follow-up. A significant and sustained increase was observed in achieving targets for HbA1C, BP and cholesterol.
Key Words: diabetes myocardial infarction insulin infusion glycosylated HbA1C mortality.
References
- Fisher M. Diabetes: can we stop the time bomb? Heart 2003;89:ii28-30.[Abstract/Free Full Text]
- Paquot N., Scheen AJ Prevention of cardiovascular disease in type 2 diabetes. Rev Med Liege 2003;58:271-4.[Medline]
[Order article via Infotrieve]
- Kuller LH, Velentgas P., Barzilay J., Beauchamp NJ, O'Leary DH, Savage PJ Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000;20:823-9.[Abstract/Free Full Text]
- Kaur J., Sing P., Sowers JR Diabetes and cardiovascular diseases. Am J Ther 2002; 9:510-15.[CrossRef][Medline]
[Order article via Infotrieve]
- Moejko-Pastewka B., Taton J., Haczynski J., Strojek K., Ametov AS, Milicevic Z. Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction. Acta Diabetol 2003;40:S354-S357.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Malmberg K., Ryden L., Efendic S. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57-65.[Abstract]
- Malmberg K. R Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-15.
- Malmberg K., Norhammar A., Wedel H., Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.[Abstract/Free Full Text]
- Almbrand B., Johannesson M., Sjostrand B., Malmberg K., Ryden L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 2000;21:733-9.[Abstract/Free Full Text]
- Davies MJ, Lawrence IG DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction): theory and practice. Diabetes Obes Metab 2002;4:289-95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Malmberg K. Role of insulin glucose infusion in acute myocardial infarction (DIGAMI) study. Endocr Pract 2004;10(2):13-16.[Medline]
[Order article via Infotrieve]
The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6,
396-399 (2004)
DOI: 10.1177/14746514040040060601

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|